EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget’s disease (EMPD-HER2DOC)

Ikuko Hirai iD, Keiji Tanese, Yoshio Nakamura, Keitaro Fukuda, Takeshi Ouchi, Tetsu Hayashida, Kaori Kameyama, Takayuki Abe, Masayuki Amagai, Takeru Funakoshi iD

The Oncologist · 06.09.2024 · 29 (9) · e1201-e1208

DOI: 10.1093/oncolo/oyae097 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 01.06.2024. Verfasst von Ikuko Hirai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582Japan. Hauptthemen laut MEDLINE: Docetaxel, Paget Disease, Extramammary, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No consensus has been reached regarding the optimal chemotherapy for metastatic extramammary Paget’s disease (EMPD), a rare cutaneous adenocarcinoma, because of the lack of solid evidence from prospective trials. However, the immunohistochemical profile of EMPD reportedly resembles that of breast cancer, particularly in terms of human epidermal growth factor receptor 2 (HER2) expression, suggesting that HER2 is a promising therapeutic target for advanced HER2-positive EMPD.

Methods

In this phase II single-arm trial, 13 Japanese patients received intravenous trastuzumab (loading dose of 8 mg/kg and maintenance dose of 6 mg/kg) and docetaxel (75 mg/m2) every 3 weeks for up to 2 years. The docetaxel dose was reduced or discontinued according to its toxicity. The primary trial endpoints were objective response rate (ORR) after 3 cycles of treatment and safety throughout the study period.

Results

All 13 patients completed 3 cycles of combination therapy. The median follow-up was 27.9 months. The ORR was 76.9% (n = 10/13; 90% CI, 50.5-93.4). Frequently observed adverse events were neutropenia (100%), hypoalbuminemia (84.6%), and mucocutaneous infection (84.6%), all of which were well tolerated.

Conclusion

The combination of docetaxel and trastuzumab demonstrated a favorable clinical effect and acceptable tolerability, which makes it a good treatment option for HER2-positive metastatic EMPD (ClinicalTrials.gov Identifier: UMIN000021311, jRCTs031180073).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelPaget Disease, ExtramammaryTrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansAgedFemaleMaleMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

HER2chemotherapydocetaxelextramammary Paget’s diseasetrastuzumab

Substanzen

DocetaxelTrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582Japan.
  • Department of Surgery, Keio University School of Medicine, Tokyo 160-8582Japan.
  • Department of Pathology, Keio University School of Medicine, Tokyo 160-8582Japan.
  • Clinical and Translational Research Center, Keio University School of Medicine, Tokyo 160-8582Japan.
  • Kyoto Women's University, Faculty of Data Science, Kyoto 605-8501Japan.

ORCID-Profile: Ikuko Hirai, Takeru Funakoshi

Zitieren

APA

Hirai, I., Tanese, K., Nakamura, Y., Fukuda, K., Ouchi, T., Hayashida, T., Kameyama, K., Abe, T., Amagai, M., & Funakoshi, T. (2024). Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget’s disease (EMPD-HER2DOC). The Oncologist, 29(9), e1201-e1208. https://doi.org/10.1093/oncolo/oyae097

Vancouver

Hirai I, Tanese K, Nakamura Y, Fukuda K, Ouchi T, Hayashida T, et al. Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget’s disease (EMPD-HER2DOC). The Oncologist. 2024;29(9):e1201-e1208. doi:10.1093/oncolo/oyae097

BibTeX
@article{Hirai2024,
  author = {Hirai, Ikuko and Tanese, Keiji and Nakamura, Yoshio and Fukuda, Keitaro and Ouchi, Takeshi and Hayashida, Tetsu and Kameyama, Kaori and Abe, Takayuki and Amagai, Masayuki and Funakoshi, Takeru},
  title = {Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget’s disease (EMPD-HER2DOC)},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {9},
  pages = {e1201--e1208},
  doi = {10.1093/oncolo/oyae097}
}
Kostenlos starten →